|Bid||3.0700 x 0|
|Ask||3.1100 x 0|
|Day's Range||3.0400 - 3.2000|
|52 Week Range||2.6000 - 6.9000|
|Beta (3Y Monthly)||1.61|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
VANCOUVER , June 24, 2019 /CNW/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Brinavess™ (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF). "The resubmission of the Brinavess NDA is a major milestone for Correvio and is the culmination of substantial effort by our employees and the investigators who have dedicated themselves toward investigating this potential new treatment option for adult patients with recent onset AF," said Mark H.N. Corrigan , MD, CEO of Correvio.
Statistically speaking, long term investing is a profitable endeavour. But no-one is immune from buying too high...
On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 23 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by ...
Mark H.N. Corrigan , MD Commences Role as CEO, effective March 14, 2019 Company on Track to Resubmit Brinavess NDA in Q2 2019 Management to Host Conference Call and Webcast Today, May 8, 2019 at 8:30 a.m. ...
Conference Call Scheduled for Wednesday, May 8, 2019 at 8:30 a.m. Eastern ( 5:30 a.m. Pacific) NASDAQ: CORV TSX: CORV VANCOUVER , May 1, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: ...
NASDAQ: CORV TSX: CORV Seven Data Abstracts Selected for Poster Presentations VANCOUVER , April 3, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company ...
VANCOUVER, March 20, 2019 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of new Brinavess® (vernakalant hydrochloride, IV) data at the American College of Cardiology 2019 Annual Meeting taking place March 16-18, 2019, in New Orleans. This poster presentation highlights reduced hospitalization in patients treated with Brinavess, Correvio's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), from a clinical survey assessing patients with acute AF at the Hillel Yaffe Medical Center located in Hadera, Israel. This presentation, titled "Intravenous Vernakalant for the Treatment of New-Onset Atrial Fibrillation in the Emergency Department," was given by Jameel Mohsen, MD, Hillel Yaffe Medical Center.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are moreRead More...
VANCOUVER, March 14, 2019 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV), ("Correvio" or the "Company"), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has entered into an At the Market Sales Issuance Agreement dated March 13, 2019 (the "Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor") as agent, pursuant to which the Company may, from time to time sell, through "at-the-market" offerings on the Nasdaq Capital Market or another existing trading market in the United States with Cantor as agent, such number of common shares as would have an aggregate offer price of up to US$50,000,000 subject to a limit of US$12,000,000 under the ATM Prospectus Supplement (as defined below). Cantor, at Correvio's discretion and instruction, will use its commercially reasonable efforts to sell the common shares at market prices from time to time.
VANCOUVER , March 11, 2019 /CNW/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced an amendment to its existing agreement with CRG Servicing LLC ("CRG") dated May 11, 2017 (the "Amending Agreement"), which provides for an increase in capital available to the Company. Under the terms of the amended agreement, Correvio is now eligible to receive up to an additional $10 million . Under the Amending Agreement, Correvio will pay a small access fee to CRG. The additional funding may be drawn at Correvio's discretion in increments of $2.5 million through September 30, 2019 and there will be prepayment premium associated with any such draw-down. "This amended credit facility provides important non-dilutive, near-term capital as well as greater financial flexibility to achieve our corporate objectives this year," said William Hunter , MD, CEO of Correvio. "Based on our current operating plan, the net proceeds from CRG, combined with our existing cash, provide us with enough capital to get an answer from the U.S. Food and Drug Administration on the Brinavess® New Drug Application which we remain on track to resubmit the Brinavess NDA during the second quarter of 2019.